Tag Archive | "partnering agreements"

Endo International sells urology portfolio to Boston Scientific

Tags: , ,


Endo International is selling its men’s health and prostate urology businesses to Boston Scientific Corp. for $1.6 billion, as it attempts to refocus its efforts on more lucrative parts of its portfolio and regain revenue after a rocky 2014. Read the full story

Athersys and Chugai announce pharma licensing deal for ischemic stroke

Tags: , , , ,


Athersys and Chugai Pharmaceutical have announced a partnership and pharma licensing agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Read the full story

GSK announces grant to IAVI for human vaccines project

Tags: , ,


The International AIDS Vaccine Initiative has received a grant of US$350,000 from GSK to support implementation of the Human Vaccines Project, Read the full story

Hikma and Eisai form a pharma partnership for Fycompa

Tags: , , ,


Hikma Pharmaceuticals announces a pharma partnership with Eisai for the distribution of Fycompa. Read the full story

Trends in Therapeutic Partnering

Tags: ,


The Trends in Therapeutic Partnering report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014. Read the full story

Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

Tags: , , , , , , ,


The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

 

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

 

This report contains links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities.

 

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

 

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

 

Chapter 4 provides a review of the leading collaborative R&D deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 5 provides a comprehensive review of collaborative R&D financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

 

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of collaborative R&D deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 8 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2009.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

 

Report scope

 

Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.

 

Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

 

  • Trends in collaborative R&D dealmaking in the biopharma industry since 2009
  • Analysis of collaborative R&D deal structure
  • Case studies of real-life collaborative R&D deals
  • Comprehensive listing of collaborative R&D deals since 2009
  • Access to collaborative R&D contract documents
  • Key financial benchmarks for headline, upfront, milestone and royalty rates
  • The leading collaborative R&D deals by value since 2009
  • Most active collaborative R&D dealmakers since 2009
  • The leading collaborative R&D partnering resources

 

In Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

 

The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Read the full story

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

Tags: , , ,


The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

 

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

 

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

 

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

 

Chapter 4 provides a review of the leading licensing deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

 

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2009.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing dealmaking, enabling thorough learning, education and due diligence prior and during the licensing dealmaking process.

 

Report scope

 

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.

 

Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

 

  • Trends in licensing dealmaking in the biopharma industry since 2009
  • Analysis of licensing deal structure
  • Case studies of real-life licensing deals
  • Comprehensive listing of licensing deals since 2009
  • Access to licensing contract documents
  • Key financial bnchmarks for headline, upfront, milestone and royalty rates
  • The leading licensing deals by value since 2009
  • Most active licensing dealmakers since 2009
  • The leading licensing partnering resources

In Licensing Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

Read the full story

Top 50 Big Pharma Partnering and M&A Deal Trends

Tags: , , , , ,


The Top 50 Big Pharma Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. Read the full story

Abbvie strikes a pharma alliance with Infinity Pharma

Tags: , , ,


Infinity Pharmaceuticals and AbbVie have entered into a global pharma alliance to develop and commercialize duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Read the full story

Pharma and biotech clinical stage partnering – recent trends 2009 to 2014

Tags: , , , , ,


Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials Read the full story